Fingolimod treatment abrogates chikungunya virus–induced arthralgia
- 1 February 2017
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (375)
Abstract
Abrogation of pathogenic CD4 + T cells to the joints with fingolimod (FTY720) treatment prevents chikungunya virus–induced joint pathology.Keywords
Funding Information
- Agency for Science, Technology and Research (F00018)
This publication has 47 references indexed in Scilit:
- Viperin restricts chikungunya virus replication and pathologyJournal of Clinical Investigation, 2012
- Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoproteinEMBO Molecular Medicine, 2012
- A Mouse Model of Chikungunya Virus–Induced Musculoskeletal Inflammatory DiseaseThe American Journal of Pathology, 2011
- The Acute Phase of Chikungunya Virus Infection in Humans Is Associated With Strong Innate Immunity and T CD8 Cell ActivationThe Journal of Infectious Diseases, 2010
- Chikungunya Virus Arthritis in Adult Wild-Type MiceJournal of Virology, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Theiler's Virus Infection Induces a Predominant Pathogenic CD4+T Cell Response to RNA Polymerase in Susceptible SJL/J MiceJournal of Virology, 2009
- Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virusVaccine, 2008
- Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirusJournal of General Virology, 2007
- Genome Microevolution of Chikungunya Viruses Causing the Indian Ocean OutbreakPLOS Medicine, 2006